E-drug: Patient education (cont'd)
---------------------------------------------------------------------
I searched with interest the Australian patient information leaflets web
site (www.appco.com.au/appguide). Many thanks to Andrew for the
information. However, posted patient information leaflets lack clear
adverse drug reaction communications. For example, Serzone
(nefazodone), the antidepressant med, has well documented liver
toxicity yet the provided Serzone's patient information leaflet did not
adequately address this serious adverse drug reaction. Serzone was
suspended from the Canadian market few weeks ago because of its
liver toxicity.
Thanks,
Sana R. Sukkari
Oncology/Palliative Care Pharmacist
Ontario, Canada
e-mail: ssukkari@jbmh.com
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug